{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00395200",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MRCRG44871"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "REC Reference: 07/Q0108/104"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "University of Cambridge",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)",
      "OfficialTitle": "Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis",
      "Acronym": "MSCIMS"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2011",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2008"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2010",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2010",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "November 1, 2006",
      "StudyFirstSubmitQCDate": "November 1, 2006",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 2, 2006",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 22, 2011",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 25, 2011",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Peter Connick",
        "ResponsiblePartyInvestigatorTitle": "Research Associate",
        "ResponsiblePartyInvestigatorAffiliation": "University of Cambridge"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University of Cambridge",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Cambridge University Hospitals NHS Foundation Trust",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Medical Research Council",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Hypothesis: Intravenous administration of bone marrow-derived autologous adult human mesenchymal stem cells is a safe novel therapeutic approach for patients with multiple sclerosis.\n\nMesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) is a phase I/IIA trial designed to establish the safety of intravenous administration of bone marrow-derived autologous adult human mesenchymal stem cells to patients with multiple sclerosis.",
      "DetailedDescription": "Disease under investigation: Multiple Sclerosis\n\nPhase: I/IIA\n\nNumber of patients: 10\n\nDesign: 18 month cross over, single treatment at 6 months\n\nIntervention: Administration of bone marrow-derived autologous mesenchymal stem cells\n\nRoute of administration: Intravenous\n\nDose: Up to 2,000,000 Mesenchymal Stem Cells per kilogram\n\nSource of patients: Referrals accepted from Neurologists in East Anglia and North London, UK\n\nReferral Criteria: (all 3 required)\n\nClinically definite multiple sclerosis\nExpanded Kurtzke Disability Status Score 2.0 - 6.5 (inclusive)\n\nEvidence of optic nerve damage by\n\nhistory of optic neuritis, or\nrelative afferent pupillary defect, or\noptic atrophy on fundoscopy, or\nabnormal visual evoked potential from either or both eyes suggestive of demyelination\n\nPrimary Objective: Establish the safety of intravenously administered bone marrow-derived autologous mesenchymal stem cells at a dose of up to 2,000,000 cells/kg over 12 months by monitoring adverse reactions.\n\nSecondary Objectives: Explore the efficacy of intravenously administered bone marrow-derived autologous mesenchymal stem cells at a dose of up to 2,000,000 cells/kg over 12 months on visual function by clinical, neurophysiological, and imaging assessments.\n\nOutcome Measures:\n\nPrimary\n\nAdverse events\n\nSecondary\n\nVisual function (acuity and colour)\nVisual evoked potential latency\nOptic nerve Magnetisation Transfer Ratio\nRetinal nerve fibre layer thickness (by optical coherence tomography)\nBrain lesion Magnetisation Transfer Ratio\nMRI brain T1 hypointensity load\nT cell response suppression\n\nTertiary\n\nMultiple Sclerosis Functional Composite Score\nExpanded Kurtzke Disability Status Score"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Multiple Sclerosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Multiple Sclerosis",
          "Safety",
          "Therapeutics",
          "Mesenchymal Stem Cells",
          "Multipotent Mesenchymal Stromal Cells",
          "Optic Neuritis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC Treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: MSC Treatment"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Procedure",
            "InterventionName": "MSC Treatment",
            "InterventionDescription": "Intravenous administration of up to 2x10^6 autologous MSCs per kg",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC Treatment"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Mesenchymal Stem Cells",
                "Multipotent Mesenchymal Stem Cells",
                "Multipotent Mesenchymal Stromal Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse events",
            "PrimaryOutcomeTimeFrame": "0,1,2,3,4,12 and 52 weeks post treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Visual function (acuity and colour)",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Visual evoked potential latency",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Optic nerve Magnetisation Transfer Ratio",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Retinal nerve fibre layer thickness (by optical coherence tomography)",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Brain lesion Magnetisation Transfer Ratio",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "MRI brain T1 hypointensity load",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Multiple Sclerosis Functional Composite Score",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Expanded Kurtzke Disability Status Score",
            "SecondaryOutcomeTimeFrame": "12 and 52 weeks post treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nClinically definite multiple sclerosis\nExpanded Kurtzke Disability Status Score 2.0 - 6.5 (inclusive)\nEvidence of optic nerve damage by:\nhistory of optic neuritis, or\nrelative afferent pupillary defect, or\noptic atrophy on fundoscopy, or\nabnormal visual evoked potential from either or both eyes suggestive of demyelination\nProlonged visual evoked potential P100 latency with preserved waveform\nT2 lesion on MRI optic nerve\nRetinal nerve fibre layer thickness on optical coherence tomography > 40 microns\n\nExclusion Criteria:\n\nAge < 18 years\nAge > 65 years\nPatient lacks capacity to give informed consent\nPresence of a severe bleeding disorder\nPlanning a pregnancy during the trial period\nCurrent MS disease modifying therapy",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Siddharthan Chandran, MBChB, PhD",
            "OverallOfficialAffiliation": "University of Cambridge",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of Cambridge Dept of Clinical Neurosciences",
            "LocationCity": "Cambridge",
            "LocationState": "Cambridgeshire",
            "LocationZip": "CB2 0PY",
            "LocationCountry": "United Kingdom"
          },
          {
            "LocationFacility": "University College London Institute of Neurology",
            "LocationCity": "London",
            "LocationZip": "WC1N 3BG",
            "LocationCountry": "United Kingdom"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "21366911",
            "ReferenceType": "background",
            "ReferenceCitation": "Connick P, Kolappan M, Patani R, Scott MA, Crawley C, He XL, Richardson K, Barber K, Webber DJ, Wheeler-Kingshott CA, Tozer DJ, Samson RS, Thomas DL, Du MQ, Luan SL, Michell AW, Altmann DR, Thompson AJ, Miller DH, Compston A, Chandran S. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011 Mar 2;12:62. doi: 10.1186/1745-6215-12-62."
          },
          {
            "ReferencePMID": "22236384",
            "ReferenceType": "derived",
            "ReferenceCitation": "Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, Compston A, Scott MA, Miller DH, Chandran S. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012 Feb;11(2):150-6. doi: 10.1016/S1474-4422(11)70305-2. Epub 2012 Jan 10."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "University of Cambridge Dept. of Clinical Neurosciences",
            "SeeAlsoLinkURL": "http://www-neurosciences.medschl.cam.ac.uk"
          },
          {
            "SeeAlsoLinkLabel": "UCL Institute of Neurology",
            "SeeAlsoLinkURL": "http://www.ion.ucl.ac.uk"
          },
          {
            "SeeAlsoLinkLabel": "Study protocol and baseline characteristics of the cohort",
            "SeeAlsoLinkURL": "http://www.trialsjournal.com/content/12/1/62/abstract"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009103",
            "ConditionMeshTerm": "Multiple Sclerosis"
          },
          {
            "ConditionMeshId": "D000012598",
            "ConditionMeshTerm": "Sclerosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000020278",
            "ConditionAncestorTerm": "Demyelinating Autoimmune Diseases, CNS"
          },
          {
            "ConditionAncestorId": "D000020274",
            "ConditionAncestorTerm": "Autoimmune Diseases of the Nervous System"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000003711",
            "ConditionAncestorTerm": "Demyelinating Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11212",
            "ConditionBrowseLeafName": "Multiple Sclerosis",
            "ConditionBrowseLeafAsFound": "Multiple Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14567",
            "ConditionBrowseLeafName": "Sclerosis",
            "ConditionBrowseLeafAsFound": "Sclerosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11985",
            "ConditionBrowseLeafName": "Optic Neuritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11539",
            "ConditionBrowseLeafName": "Neuritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21251",
            "ConditionBrowseLeafName": "Demyelinating Autoimmune Diseases, CNS",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M21247",
            "ConditionBrowseLeafName": "Autoimmune Diseases of the Nervous System",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6061",
            "ConditionBrowseLeafName": "Demyelinating Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4263",
            "ConditionBrowseLeafName": "Optic Neuritis",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC11",
            "ConditionBrowseBranchName": "Eye Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M5415",
            "InterventionBrowseLeafName": "Coal Tar",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M186752",
            "InterventionBrowseLeafName": "Remestemcel-l",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Derm",
            "InterventionBrowseBranchName": "Dermatologic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infl",
            "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
          }
        ]
      }
    }
  }
}